Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EDNRA | P25101 | 6/20 | 0.56 |
| ▸ | EDNRB | P24530 | 4/20 | 0.45 |
| ▸ | ALOX12 | P18054 | 5/20 | 0.43 |
| ▸ | ESR1 | P03372 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9045300 | 0.90 | EDNRA (0.58) | EDNRAEDNRBALOX12GAANFE2L2 | |
| SCHEMBL9047672 | 0.89 | EDNRA (0.53) | EDNRAEDNRBALOX12ESR1GAA | |
| SCHEMBL9047760 | 0.88 | EDNRA (0.42) | EDNRAEDNRBALOX12ESR1MEN1 | |
| SCHEMBL9045564 | 0.87 | EDNRA (0.43) | EDNRAEDNRBALOX12ESR1MEN1 | |
| SCHEMBL9044869 | 0.87 | EDNRA (0.55) | EDNRAEDNRBALOX12GAAALOX15 | |
| SCHEMBL9045584 | 0.87 | EDNRA (0.73) | EDNRAEDNRBALDH1A1 | |
| SCHEMBL9492514 | 0.86 | EDNRA (0.54) | EDNRAEDNRBALOX12ESR1GAA | |
| SCHEMBL9044456 | 0.86 | EDNRA (0.61) | EDNRAEDNRBALOX15NFE2L2MEN1 | |
| SCHEMBL9046624 | 0.85 | EDNRA (0.78) | EDNRAEDNRBALOX12 | |
| SCHEMBL9044533 | 0.84 | EDNRA (0.40) | EDNRAEDNRBNFE2L2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0510526-B1 | Use of sulfonamides as drug and new sulfonamides | HOFFMANN LA ROCHE (CH) | 1996-12-04 | — | — | EP | disclosed |
| US-5270313-A | Treatment of circulatory disorders | HOFFMANN-LA ROCHE INC. (US) | 1993-12-14 | — | — | US | disclosed |
| EP-0510526-A1 | Use of sulfonamides as drug and new sulfonamides | F.HOFFMANN-LA ROCHE & CO. AKTIENGESELLSCHAFT (CH) | 1992-10-28 | — | — | EP | disclosed |